Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma.

Trial Details

NCT ID
NCT05620693
Phase
NA
Sponsor
Shenzhen University General Hospital
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • NY-ESO-1 TCR-T
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • Aged 18-70 (≥ 18, ≤ 70), regardless of gender;
  • Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
  • Late recurrent or metastatic soft tissue sarcoma confirmed by histopathology; Progress after receiving first-line treatment;
  • According to RECIST 1.1 standard, there are clear assessable lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →